These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 15301561)

  • 61. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
    Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
    Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA; Villela R; Silverberg MS; Greenberg GR
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease.
    Conklin LS; Cohen B; Wilson L; Cuffari C; Oliva-Hemker M
    Nat Rev Gastroenterol Hepatol; 2010 Mar; 7(3):174-7. PubMed ID: 20203680
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Adverse reactions to infliximab and the outcome of desensitization.
    Mourad AA; Boktor MN; Yilmaz-Demirdag Y; Bahna SL
    Ann Allergy Asthma Immunol; 2015 Aug; 115(2):143-6. PubMed ID: 26093777
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
    Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Infliximab therapy in Crohn's disease: safety issues.
    Hommes DW; van Deventer SJ
    Neth J Med; 2003 Apr; 61(4):100-4. PubMed ID: 12852717
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
    Martín-de-Carpi J; Pociello N; Varea V
    J Crohns Colitis; 2010 Nov; 4(5):594-8. PubMed ID: 21122566
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
    Bortlik M; Duricova D; Malickova K; Machkova N; Bouzkova E; Hrdlicka L; Komarek A; Lukas M
    J Crohns Colitis; 2013 Oct; 7(9):736-43. PubMed ID: 23200919
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
    Aringer M; Graninger WB; Steiner G; Smolen JS
    Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Infliximab.
    Valle E; Gross M; Bickston SJ
    Expert Opin Pharmacother; 2001 Jun; 2(6):1015-25. PubMed ID: 11585004
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Infliximab use in luminal Crohn's disease.
    Richter JA; Bickston SJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic.
    Wetter DA; Davis MD
    Mayo Clin Proc; 2009 Nov; 84(11):979-84. PubMed ID: 19880688
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model.
    Crandall WV; Mackner LM
    Aliment Pharmacol Ther; 2003 Jan; 17(1):75-84. PubMed ID: 12492735
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Strategies targeting tumor necrosis factor in Crohn's disease.
    Sandborn WJ
    Acta Gastroenterol Belg; 2001; 64(2):170-2. PubMed ID: 11475128
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Early combined immunosuppression in Crohn's disease.
    Lees CW; Satsangi J
    Lancet; 2008 Jun; 371(9629):1995; author reply 1996-7. PubMed ID: 18555905
    [No Abstract]   [Full Text] [Related]  

  • 76. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab).
    Garcia-Planella E; Domènech E; Esteve-Comas M; Bernal I; Cabré E; Boix J; Gassull MA
    Eur J Gastroenterol Hepatol; 2003 Apr; 15(4):351-4. PubMed ID: 12655253
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Perianal Crohn's disease and infliximab therapy.
    McNamara DA; Brophy S; Hyland JM
    Surgeon; 2004 Oct; 2(5):258-63. PubMed ID: 15570844
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease.
    Velayos FS; Sandborn WJ
    Inflamm Bowel Dis; 2004 Sep; 10(5):657-60. PubMed ID: 15472531
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion.
    Riegert-Johnson DL; Godfrey JA; Myers JL; Hubmayr RD; Sandborn WJ; Loftus EV
    Inflamm Bowel Dis; 2002 May; 8(3):186-91. PubMed ID: 11979139
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease.
    Drini M; Prichard PJ; Brown GJ; Macrae FA
    Med J Aust; 2008 Oct; 189(8):464-5. PubMed ID: 18928444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.